Moderna (MRNA) Total Liabilities (2017 - 2026)
Moderna (MRNA) posted quarterly Total Liabilities of $4.2 billion for Q2 2026, up 60.86% year-over-year from $2.6 billion in Q2 2025, and up 2.94% on a QoQ basis from $4.1 billion in Q1 2026.
Moderna (MRNA) Total Liabilities (2017 - 2026) Analysis & Trends
Moderna has reported Total Liabilities for 10 years, with the latest figure at $4.2 billion in Q2 2026.
- Total Liabilities for Q2 2026 came in at $4.2 billion, up 60.86% year-over-year; the trailing twelve-month figure through Jun 2026 was $4.2 billion (up 60.86% YoY), and the FY2025 annual result was $3.7 billion, up 13.79% from the prior year.
- Total Liabilities grew to $4.2 billion in Q2 2026, from $4.1 billion in the prior quarter.
- Over five years, Total Liabilities peaked at $10.5 billion in Q1 2022 and troughed at $2.6 billion in Q2 2025.
- A 5-year average of $5.0 billion and a median of $4.1 billion in 2026 frame the typical range for Total Liabilities.
- The widest annual swing landed in 2023, when Total Liabilities slumped 50.05%; it then jumped 60.86% in 2026.
- A 5-year view of Total Liabilities shows it stood at $6.7 billion in 2022, then slumped by 32.12% to $4.6 billion in 2023, then fell by 29.11% to $3.2 billion in 2024, then grew by 13.79% to $3.7 billion in 2025, then gained by 13.88% to $4.2 billion in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $4.2 billion in Q2 2026, $4.1 billion in Q1 2026, and $3.7 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn | 4.20 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.20 Bn |
| Mar 31, 2026 | 4.08 Bn |
| Dec 31, 2025 | 3.69 Bn |
| Sep 30, 2025 | 2.81 Bn |
| Jun 30, 2025 | 2.61 Bn |
| Mar 31, 2025 | 2.64 Bn |
| Dec 31, 2024 | 3.24 Bn |
| Sep 30, 2024 | 3.88 Bn |
| Jun 30, 2024 | 3.97 Bn |
| Mar 31, 2024 | 3.91 Bn |
| Dec 31, 2023 | 4.57 Bn |
| Sep 30, 2023 | 6.00 Bn |
| Jun 30, 2023 | 4.94 Bn |
| Mar 31, 2023 | 5.26 Bn |
| Dec 31, 2022 | 6.74 Bn |
| Sep 30, 2022 | 8.06 Bn |
| Jun 30, 2022 | 8.06 Bn |
| Mar 31, 2022 | 10.53 Bn |
| Dec 31, 2021 | 10.52 Bn |
| Sep 30, 2021 | 10.80 Bn |